A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC).

Daniel M. Geynisman,Yuanyuan Zha,Rangesh Kunnavakkam,Mebea Aklilu,Daniel Virgil Thomas Catenacci,Blase N. Polite,Cara A. Rosenbaum,Azadeh Namakydoust,Theodore Karrison,Thomas F. Gajewski,Hedy L. Kindler

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC).

2017

Daniel M. Geynisman
Yuanyuan Zha
Rangesh Kunnavakkam
Mebea Aklilu
Daniel Virgil Thomas Catenacci
Blase N. Polite
Cara A. Rosenbaum
Azadeh Namakydoust
Theodore Karrison
Thomas F. Gajewski
Hedy L. Kindler

2561 Background: CEA is expressed in >90% of PC and may be an appropriate immunotherapy target. CEA is poorly immunogenic due to immune tolerance; CAP1-6D, an altered peptide ligand can help bypass...

Keywords:

Pathology
CEA Peptide
Immunotherapy
Cancer research
Carcinoembryonic antigen
Peptide
Immune tolerance
Medicine
Adenocarcinoma
peptide ligand
pilot phase
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations